ISC hpNSC
Alternative Names: hpNSC; Human parthenogenetic neural stem cells - International Stem Cell Corporation; ISC-hpNSCLatest Information Update: 28 May 2025
At a glance
- Originator Duke University; International Stem Cell Corporation
- Developer International Stem Cell Corporation; Tulane University
- Class Antiparkinsonians; Cell therapies; Neural stem cell therapies; Pluripotent stem cell therapies
- Mechanism of Action Dopaminergic cell replacements; Nervous system modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Brain injuries; Parkinson's disease; Stroke
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Parkinson's-disease in Australia (Intracerebral, Injection)
- 28 May 2025 No recent reports of development identified for preclinical development in Brain injuries in USA (Injection)
- 28 May 2025 No recent reports of development identified for preclinical development in Stroke in USA